Clin Mol Hepatol.
2024 Oct;30(4):994-996. 10.3350/cmh.2024.0552.
Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”
- Affiliations
-
- 1National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China
- 2Clinical Epidemiology and EBM Unit, Beijing Clinical Research Institute, Beijing, China
- 3Liver Research Center, Beijing Friendship Hospital, Capital Medical University; State Key Lab of Digestive Health, Beijing, China
- KMID: 2560106
- DOI: http://doi.org/10.3350/cmh.2024.0552
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”
- Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”
- Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
- Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
- Anti-viral Treatment of Chronic Hepatitis B
